Form 4 for ACXP Acurx Pharmaceuticals, Inc.
Accepted 2024-01-04 00:00:00 ET · period of report 2024-01-03 · accession 0001104659-24-001373 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-01-04 | 2024-01-03 | ACXP | LUCI DAVID P | Pres, CEO, Dir, 10% | M - OptEx | $3.55 | +19.7K | 1.05M | +2% | +$70.1K |
| D | 2024-01-04 | 2024-01-03 | ACXP | LUCI DAVID P | Pres, CEO, Dir, 10% | M - OptEx | $0.00 | -19.7K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-01-03 | M | A | 19,737 | $3.55 | 1,048,197 | D | — | — | |
| 2 | Derivative | Warrants for Common Stock | 2024-01-03 | M | D | 19,737 | $0.00 | 0 | D | $3.55 · 2023-01-27 to 2024-01-27 | 19,737 Common Stock |